Having a few blue chip ASX 200 shares in a portfolio can be a great foundation to build from.
But which blue chips could be top picks for a $10,000 investment right now?
Let's take a look at three that brokers are tipping as buys to their clients. Here they are:
Northern Star Resources Ltd (ASX: NST)
If you are wanting some exposure to the sky high gold price, then Northern Star could be the ASX 200 blue chip share to buy.
The team at Morgans thinks that the gold miner's shares are great value following significant share price weakness following an update. It said:
Overall, the update disappointed and reflected in the share price action (–8.6%). FY26 adjustments were poorly flagged, with the new AISC midpoint +12% above consensus along with additional growth CAPEX items. We adjust our forecasts in line with updated guidance and reduce our price target to A$21.78ps (previously A$25.32ps). Today's sell-off reflects a rebasing of NST's share price following a strong FY25 performance (aided by the macro). Looking ahead, operational execution and disciplined capital cost control will be key to unlocking further value.
Morgans has a buy rating and $21.78 price target on its shares.
ResMed Inc. (ASX: RMD)
Another ASX 200 blue chip share that brokers are bullish on is ResMed.
It is a sleep disorder treatment company with a world class portfolio of products. And with its shares trading on lower than normal multiples, Bell Potter thinks now could be the time to buy. It said:
GLP-1 headlines knocked the 12MF P/E from ~32x to ~24x currently (which we view as being over-done), while earnings remain robust, with EPS 2yr CAGR of 11%, a strong balance sheet, and an FY256 ROE at 24%, presents an attractive opportunity, and our preferred way, of including defence into a portfolio.
Bell Potter has named ResMed on its Australian equities panel. These are its "favoured Australian equities offer attractive risk-adjusted returns over the long term."
Treasury Wine Estates Ltd (ASX: TWE)
Finally, the team at Morgans also thinks that Treasury Wine could be an ASX 200 blue chip share to buy this month.
Although recent updates have been disappointing, Morgans thinks that its shares are too cheap and that patient investors should be taking advantage of this. It said:
While not without risk given industry and macro headwinds, TWE's trading multiples look far too cheap (FY25/26 PE of only 13.6/12.6x) and we maintain a BUY rating. However, we recognise the stock is lacking near-term catalysts and therefore patience is required given a material rerating may take time to eventuate.
Morgans has a buy rating and $10.25 price target on its shares.
